{"id":"W4415671112","doi":"10.1016/j.htct.2025.104836","title":"HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH TRANSPLANT-INELIGIBLE OR TRANSPLANT-DEFERRED NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) IN THE PHASE 3 CEPHEUS TRIAL","year":2025,"lang":"en","type":"article","venue":"Hematology Transfusion and Cell Therapy","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Daratumumab; Multiple myeloma; Quality of life (healthcare); Bortezomib; Population; Clinical trial; Phases of clinical research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000923981,0.0002445033,0.0007572374,0.0001128612,0.0002394632,0.0003743444,0.0001952394,0.0002718535,0.001137912],"category_scores_gemma":[0.0005185595,0.0001067978,0.0007528634,0.0002143422,0.0002126086,0.0002433235,0.0002571476,0.000813562,0.0001175873],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004903229,"about_ca_system_score_gemma":0.0004713471,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005834033,"about_ca_topic_score_gemma":0.001579528,"domain_scores_codex":[0.9997774,0.0001080533,0.00001525059,0.00003384995,0.00002355822,0.00004187991],"domain_scores_gemma":[0.9997424,0.00005025979,0.0000757874,0.00001550384,0.00001257511,0.0001033824],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6180363,0.01506278,0.1779171,0.0007699713,0.002611064,0.0003955577,0.000262587,0.003140101,0.01114782,0.0004684938,0.006424838,0.1637634],"study_design_scores_gemma":[0.2031252,0.2792129,0.4993955,0.000153639,0.001771079,0.0007989068,0.0001688284,0.004342185,0.003155271,0.0006609052,0.007173119,0.0000425808],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9977029,0.001172784,0.00009723387,0.0001261414,0.00003304968,0.000125766,0.0002497497,0.000005077931,0.0004873387],"genre_scores_gemma":[0.9983809,0.0003992358,0.0001669472,0.0001736272,0.00003681794,0.0001382041,0.0004362054,9.779139e-7,0.0002670246],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001137912,"threshold_uncertainty_score":0.004886508,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03849506143546937,"score_gpt":0.3321415740261922,"score_spread":0.2936465125907228,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}